14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ARDC vs JRI: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Ares Dynamic Credit Allocation Fund, Inc. (ARDC) captures the overall head-to-head institutional edge over Nuveen Real Asset Income And Growth Fund (JRI) on higher Unified Composite conviction (39.4/100 SELL vs. 39.7/100 SELL) after splitting the core matrix 1–3 (led by composite factor balance), while JRI wins 1–0 across the 6-pillar growth and valuation breakdown. ARDC trades at $11.37 (N/M Forward P/E, N/A operating margin) versus JRI at $11.09 (N/M Forward P/E, N/A operating margin).
Growth vs. Quality Trade-Off: ARDC earns the overall head-to-head edge with a stronger Unified Composite Score (39.4/100 SELL vs. JRI 39.7/100 SELL) and 0.35β · 15% Vol risk profile, whereas JRI leads top-line expansion (N/A YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
Defensive Composite Rating Caution: Although ARDC compares more favorably head-to-head, both ARDC (39.4/100 SELL) and JRI (39.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: ARDC is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 42.6); meanwhile JRI is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 46.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ARDC vs JRI. Trailing 12-month operating profitability (ARDC N/A vs JRI N/A) and valuation multiples (ARDC N/M vs JRI N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with $392.9M market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ARDC vs JRI Key Questions & Quantitative Answers
As of Nov 16, 2026, Ares Dynamic Credit Allocation Fund, Inc. (ARDC) captures the overall head-to-head institutional edge over Nuveen Real Asset Income And Growth Fund (JRI) on higher Unified Composite conviction (39.4/100 SELL vs. 39.7/100 SELL) after splitting the core matrix 1–3 (led by composite factor balance), while JRI wins 1–0 across the 6-pillar growth and valuation breakdown. ARDC trades at $11.37 (N/M Forward P/E, N/A operating margin) versus JRI at $11.09 (N/M Forward P/E, N/A operating margin). Growth vs. Quality Trade-Off: ARDC earns the overall head-to-head edge with a stronger Unified Composite Score (39.4/100 SELL vs. JRI 39.7/100 SELL) and 0.35β · 15% Vol risk profile, whereas JRI leads top-line expansion (N/A YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although ARDC compares more favorably head-to-head, both ARDC (39.4/100 SELL) and JRI (39.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: ARDC is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 42.6); meanwhile JRI is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 46.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
JRI leads the Growth & Scale pillar: ARDC posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with JRI at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, ARDC generates N/A in USD-normalized revenue versus N/A for JRI. In operating R&D and SG&A reinvestment, ARDC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for JRI.
ARDC and JRI trade at balanced relative valuation multiples. ARDC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas JRI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ARDC (N/A ROE) versus JRI (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, ARDC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.35β · 15% Vol realized risk). By comparison, JRI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.51β · 22% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.